Expression of L1CAM and KI-67 in Endometrial Cancer of Egyptian Females: Clinical Impact and Survival

F. Gharib, Dareen Abd elaziz mohamed, B. Amer
{"title":"Expression of L1CAM and KI-67 in Endometrial Cancer of Egyptian Females: Clinical Impact and Survival","authors":"F. Gharib, Dareen Abd elaziz mohamed, B. Amer","doi":"10.1177/0300891620914173","DOIUrl":null,"url":null,"abstract":"Introduction: Endometrial adenocarcinoma is characterized by a good prognosis. However, the disease response shows a significant heterogeneity. Treatment of endometrial cancer (EC) is still based on clinico-pathological parameters, which have limited role in risk stratification. There is a need for more determinant markers, such as L1 Cell Adhesion Molecule (L1CAM), to identify patients at higher risk of relapse and tailor a more convenient treatment. L1CAM has a capacity to enhance cell motility and promote tumor invasion in different malignancies. In Egypt, the incidence rate of EC is growing over time. Especially in Elgharbiah governorate (home of this study). L1CAM expression and Ki-67 was reported and compared with other clinico-pathological criteria. Method: Seventy-six female patients of endometrial carcinomas were involved in this prospective study. The patients were treated and followed up at Tanta University Hospitals in the period between January 2015 to April 2019. L1CAM expression and Ki-67 was detected by immuno-histochemical exam and compared with other clinico-pathological criteria. Survival was assessed and compared by Kaplan-Meier curves and log-rank test. Results: Positive L1CAM expression was detected in 17 patients (22.4%) and was significantly correlated with unfavorable prognostic factors such as higher stage and grade (P= 0.021 and P =0.001 respectively), lympo-vascular invasion (P <0.001), non-endometroid type (P <0.027) and Ki-67 (P= 0.003). Univariate analysis revealed that: positive L1CAM; higher tumor grade; high stage; and non-endometrioid type were significantly associated with shorter disease-free survival (DFS) but no significant correlation was detected between Ki-67 and DFS. In multivariate analysis, positive L1CAM remained statistically significant with DFS [P =0.045; 95%CI (1.028:11.17); HR=3.38]. Conclusion: Our study indicates that L1CAM expression and Ki-67 are significantly associated with poor tumor characteristics. L1CAM is significantly associated with shorter disease-free survival and may be a helpful tool as a part of a simple clinical molecular classification for EC.","PeriodicalId":23450,"journal":{"name":"Tumori Journal","volume":"30 1","pages":"36 - 36"},"PeriodicalIF":0.0000,"publicationDate":"2020-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"1","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Tumori Journal","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1177/0300891620914173","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 1

Abstract

Introduction: Endometrial adenocarcinoma is characterized by a good prognosis. However, the disease response shows a significant heterogeneity. Treatment of endometrial cancer (EC) is still based on clinico-pathological parameters, which have limited role in risk stratification. There is a need for more determinant markers, such as L1 Cell Adhesion Molecule (L1CAM), to identify patients at higher risk of relapse and tailor a more convenient treatment. L1CAM has a capacity to enhance cell motility and promote tumor invasion in different malignancies. In Egypt, the incidence rate of EC is growing over time. Especially in Elgharbiah governorate (home of this study). L1CAM expression and Ki-67 was reported and compared with other clinico-pathological criteria. Method: Seventy-six female patients of endometrial carcinomas were involved in this prospective study. The patients were treated and followed up at Tanta University Hospitals in the period between January 2015 to April 2019. L1CAM expression and Ki-67 was detected by immuno-histochemical exam and compared with other clinico-pathological criteria. Survival was assessed and compared by Kaplan-Meier curves and log-rank test. Results: Positive L1CAM expression was detected in 17 patients (22.4%) and was significantly correlated with unfavorable prognostic factors such as higher stage and grade (P= 0.021 and P =0.001 respectively), lympo-vascular invasion (P <0.001), non-endometroid type (P <0.027) and Ki-67 (P= 0.003). Univariate analysis revealed that: positive L1CAM; higher tumor grade; high stage; and non-endometrioid type were significantly associated with shorter disease-free survival (DFS) but no significant correlation was detected between Ki-67 and DFS. In multivariate analysis, positive L1CAM remained statistically significant with DFS [P =0.045; 95%CI (1.028:11.17); HR=3.38]. Conclusion: Our study indicates that L1CAM expression and Ki-67 are significantly associated with poor tumor characteristics. L1CAM is significantly associated with shorter disease-free survival and may be a helpful tool as a part of a simple clinical molecular classification for EC.
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
L1CAM和KI-67在埃及女性子宫内膜癌中的表达:临床影响和生存
简介:子宫内膜腺癌的特点是预后良好。然而,疾病反应表现出显著的异质性。子宫内膜癌(EC)的治疗仍然基于临床病理参数,其在风险分层中的作用有限。需要更多的决定性标志物,如L1细胞粘附分子(L1 Cell Adhesion Molecule, L1CAM),来识别复发风险较高的患者,并制定更方便的治疗方案。在不同的恶性肿瘤中,L1CAM具有增强细胞运动和促进肿瘤侵袭的能力。在埃及,EC的发病率随着时间的推移而增长。特别是在Elgharbiah省(本研究的所在地)。报告L1CAM表达和Ki-67,并与其他临床病理标准进行比较。方法:对76例女性子宫内膜癌患者进行前瞻性研究。患者于2015年1月至2019年4月期间在坦塔大学医院接受治疗和随访。采用免疫组化检查检测L1CAM和Ki-67的表达,并与其他临床病理标准进行比较。生存率采用Kaplan-Meier曲线和log-rank检验进行比较。结果:17例患者(22.4%)检测到L1CAM阳性表达,其与分期、分级较高(P= 0.021、P= 0.001)、淋巴血管侵犯(P <0.001)、非子宫内膜型(P <0.027)、Ki-67 (P= 0.003)等不良预后因素显著相关。单因素分析显示:L1CAM阳性;肿瘤分级高;高阶段;非子宫内膜样型与较短的无病生存期(DFS)显著相关,但Ki-67与DFS之间无显著相关性。多因素分析中,L1CAM阳性与DFS差异有统计学意义[P =0.045;95%可信区间(1.028:11.17);HR = 3.38)。结论:我们的研究表明L1CAM的表达和Ki-67与肿瘤的不良特征有显著的相关性。L1CAM与较短的无病生存期显著相关,可能是一个有用的工具,作为EC简单临床分子分类的一部分。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
自引率
0.00%
发文量
0
期刊最新文献
PROACT 2.0: A new open-source tool to improve patient-doctor communication in clinical trials Response to lorlatinib rechallenge in a case of ALK-rearranged metastatic NSCLC with a resistance mutation to second generation TKIs The digital revolution in pathology: Towards a smarter approach to research and treatment The power of art and the powers of adolescents with cancer: Age-specific projects at Italian pediatric oncology centers bgicc 2024 abstracts
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1